Abstract 1671P
Background
The rise of the internet has transformed communication and healthcare, allowing easy access to sensitive medical test results. However, this practice lacks regulation. Breast cancer, the most common cancer in women, has seen improved survival rates, leading to more individuals living with the disease. Patients accessing their results online can pose challenges for oncologists due to the anxiety stemming from this constant access. Studies show conflicting outcomes regarding the emotional impact of this access, ranging from increased patient engagement to heightened anxiety. This study aims to investigate whether online receipt of sensitive results can worsen the emotional health of oncology patients, for instance, by intensifying anxiety symptoms.
Methods
This cross-sectional study employed a questionnaire with four sections to assess patients diagnosed with breast cancer within five years. The questionnaire covered demographic information, online test result access habits, anxiety levels during result anticipation, and validated screening tools for personality disorders (PID-5-BF), anxiety (GAD-7), and depression (PHQ-9). Sample size estimation for confidence interval calculations targeted 385 patients. The current analysis includes data from 198 respondents.
Results
Among the 198 participants, 196 (99%) were female, with only 2 (1%) being male. The majority (75.3%) received their breast cancer diagnosis within the past 1 to 5 years. In terms of cancer staging, 41.4% had early-stage disease (Stages I-III), while 57.6% had advanced-stage disease (Stage IV). Concerning online result access, 25.3% reported infrequent online result checks, while 74.2% confirmed habitual checking. During result anticipation, 64.6% expressed anxiety, primarily described as mild (62.2%). Statistical analyses indicated no significant association between online result access behavior and anxiety levels (p=0.609), anxiety disorders (p=0.411), or depressive disorders (p=0.484).
Conclusions
This interim analysis did not reveal a correlation between receiving potentially sensitive test results online and patient anxiety. Recruitment is ongoing and on target to produce a final analysis in the near future.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1627P - Long survivors after androgen deprivation therapy (ADT) with or without docetaxel for metastatic castration-sensitive prostate cancer (mCSPC): Long-term follow-up of GETUG-15
Presenter: Sarah Blanchet-Deverly
Session: Poster session 11
1628P - Factors influencing clinical and biological response in patients treated with [177Lu]Lu-PSMA-617 under France's early access program
Presenter: Vincent Habouzit
Session: Poster session 11
1629P - Lutetium-177–prostate-specific membrane antigen (177Lu-PSMA) therapy in patients (pts) with prior Radium-223 (223Ra)
Presenter: Kambiz Rahbar
Session: Poster session 11
1630P - A multicenter retrospective study on the efficacy of anti-PD-(L)1 in microsatellite unstable (MSI-H) metastatic castrate-resistant prostate cancer (mCRPC)
Presenter: Sandra Van Wilpe
Session: Poster session 11
1632P - Impact of androgen pathway inhibitors on cognitive function in elderly patients with metastatic prostate cancer: Results from the COG-PRO trial
Presenter: Antoine Boué
Session: Poster session 11
1634P - Does lower serum testosterone predict metastases-free survival in nmCRPC patients treated with novel antiandrogens? A post-hoc analysis of SPARTAN and ARAMIS
Presenter: Xudong Ni
Session: Poster session 11
1635P - Validation of automated bone scan index as a progression endpoint in two phase III studies of metastatic castration resistant prostate cancer (mCRPC) patients
Presenter: Andrea Knezevic
Session: Poster session 11